Harper L. Wilson

Harper L. Wilson

Auto-generated profile, based on publicly available information

Harper L. Wilson

University of Kentucky Medical Center, Lexington, KY 40536, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
HWHarper L. Wilson
Harper L. Wilson
RDRalph B. D'AGostino
Ralph B. D'AGostino
NMNuwan Meegalla
Nuwan Meegalla
RPRobin Petro
Robin Petro
SCSara Commander
Sara Commander
MPMercedes Porosnicu
Mercedes Porosnicu
Background To explore the genomic landscape of Head and Neck Squamous Cell Carcinoma (HNSCC) in circulation (ctDNA) and tumor (tDNA) and understand the implications of ctDNA sequencing for prognosis and precision oncology treatments. Materials and Methods This is a retrospective review of 75 HNSCC patients for both tDNA and ctDNA. Results were analyzed for concordance between tDNA and ctDNA and for their individual and combined association with demographics, survival, and presence and extent of disease at last visit (DLV). Results The 5 most frequently altered genes were TP53, CDKN2A, TERT, BRCA2, and NOTCH1. Twenty percent of patients had NOTCH1 alterations in tDNA, with none found in ctDNA. Concordance among altered genes was 13.0% and 65.3% of patients had actionable ctDNA alterations. ctDNA alterations were significantly associated with decreased overall survival (OS) and presence and extent of DLV. In DNA repair genes, alterations in ctDNA alone and combined with tDNA were significantly associated with decreased OS and presence of DLV. Similar significant associations were found in TP53 for ctDNA alone and combined with tDNA. DNA repair gene alterations in ctDNA and unique ctDNA alterations within partially concordant genes were significantly associated with decreased OS in multivariate analysis. Conclusion This study illustrates the circulating and tumor genomic profile in the largest HNSCC cohort to date, underscoring the potential utility of ctDNA in prognostication and precision oncology treatment. For the first time, the presence of ctDNA alterations and specific ctDNA sequencing results were shown to be significantly associated with poor prognosis in HNSCC. IMPLICATIONS FOR PRACTICE The use of precision genomic targeted therapies in Head and Neck Squamous Cell Carcinoma (HNSCC) lags behind many other cancers and poor survival in advanced stages indicates the urgent need for improved treatment options. This exploratory analysis of circulating tumor DNA (ctDNA) and tumor tissue DNA (tDNA) sequencing in the largest cohort to date of HNSCC patients provides a novel depiction of the ctDNA genome with two thirds of patients having actionable ctDNA alterations. We report for the first time the prognostic value of ctDNA sequencing, with the presence of ctDNA alterations, specific ctDNA alterations in DNA repair genes and TP53, and unique ctDNA alterations within partially concordant genes predicting poor survival.

22 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KBKimberly Burcher
Kimberly Burcher
AFAndrew Faucheux
Andrew Faucheux
JLJeffrey Lantz
Jeffrey Lantz
HWHarper L. Wilson
Harper L. Wilson
AAArianne Abreu
Arianne Abreu
MPMercedes Porosnicu
Mercedes Porosnicu
PARP inhibitors are currently approved for a limited number of cancers and targetable mutations in DNA damage repair (DDR) genes. In this single-institution retrospective study, the profiles of 170 patients with head and neck squamous cell cancer (HNSCC) and available tumor tissue DNA (tDNA) and circulating tumor DNA (ctDNA) results were analyzed for mutations in a set of 18 DDR genes as well as in gene subsets defined by technical and clinical significance. Mutations were correlated with demographic and outcome data. The addition of ctDNA to the standard tDNA analysis contributed to identification of a significantly increased incidence of patients with mutations in one or more genes in each of the study subsets of DDR genes in groups of patients older than 60 years, patients with laryngeal primaries, patients with advanced stage at diagnosis and patients previously treated with chemotherapy and/or radiotherapy. Patients with DDR gene mutations were found to be significantly less likely to have primary tumors within the in oropharynx or HPV-positive disease. Patients with ctDNA mutations in all subsets of DDR genes analyzed had significantly worse overall survival in univariate and adjusted multivariate analysis. This study underscores the utility of ctDNA analysis, alone, and in combination with tDNA, for defining the prevalence and the role of DDR gene mutations in HNSCC. Furthermore, this study fosters research promoting the utilization of PARP inhibitors in HNSCC precision oncology treatments.

1 March 2021 in Otolaryngology Case Reports
Verified
Journal Article
Open access
HWH.L. Wilson
H.L. Wilson
NMN. Van Maele
N. Van Maele
KIK.C. Iverson
K.C. Iverson

1 March 2021 in Otolaryngology Case Reports
Verified
Journal Article
Open access
BNBryce Noblitt
Bryce Noblitt
HWHarper Wilson
Harper Wilson
KIKenneth Iverson
Kenneth Iverson